OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

Cancers & treatments·Sequencing

Breast cancer (all types): lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersHR-positive
Screening, prevention and diagnosis1·
Early / localised1·
Other settings·1

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersScreeningMammography every one to three years from around age 40 to 50 depending on country; MRI for high-risk women.
Mammography & tomosynthesis
89

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersEarly disease, all typesBreast-conserving surgery with radiotherapy or mastectomy, sentinel node biopsy, then treatment by receptor type on the subtype pages.
HR-positive / HER2-negative breast cancerHER2-positive breast cancerTriple-negative breast cancer (TNBC)Hypofractionated radiotherapy
32

Other settings

SubgroupSettingApproachProducts and trialsEvidence
HR-positiveDuctal carcinoma in situSurgery with or without radiotherapy and endocrine therapy; active surveillance under study.
Ductal carcinoma in situ (DCIS)
-

Sequence and caution pairings

CautionApproved
Caution: DXd ADC + agents with pneumonitis risk

Enhertu and its DXd cousins can inflame the lungs; combining them with immunotherapy, radiation, or mTOR inhibitors stacks that risk.

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.